← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Sloan-Kettering Institute For Cancer Research
$203,566,253
Total funding
176
Grants
Funding over time
peak $24.5M · FY2008–25$25M$18.8M$12.5M$6.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$198,060,097 · 172
DOE$5,506,156 · 4
By mechanism
—$203,566,253 · 176
Investigators at Sloan-Kettering Institute For Cancer Research
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
THE PROSTATE CANCER CLINICAL TRIALS CONSORTIUM: APPLICATION FOR COORDINATING CENTER WITH CLINICAL RESEARCH SITE OPTION$9,756,468
· FY2015 · Department of the Army
DISSECTING AND TARGETING LATENT METASTASIS$9,145,001
· FY2012 · Department of the Army
COORDINATING CENTER APPLICATION FOR PROSTATE CANCER RESEARCH PROGRAM CLINICAL CONSORTIUM AWARD$9,086,947
· FY2009 · Department of Defense
THE PROSTATE CANCER CLINICAL TRIALS CONSORTIUM: APPLICATION FOR COORDINATING CENTER WITH AFFILIATE CLINICAL RESEARCH SITES$8,340,373
· FY2022 · Defense Health Agency
THE PROSTATE CANCER CLINICAL TRIALS CONSORTIUM: APPLICATION FOR COORDINATING CENTER WITH CLINICAL RESEARCH SITE OPTION$7,973,466
· FY2018 · Defense Health Agency
TOWARD THE PRACTICE OF PRECISION MEDICINE: A BIOMARKER VALIDATION COORDINATING CENGER$6,984,950
· FY2013 · Department of Defense
MULTIDISCIPLINARY OVARIAN CANCER OUTCOMES GROUP (MOCOG)$5,371,526
· FY2016 · Defense Health Agency
MOBILIZATION OF NEURAL PRECURSORS IN THE CIRCULATING BLOOD OF PATIENTS WITH MULTIPLE SCLEROSIS$5,339,776
· FY2009 · Department of the Army
PHASE 2 STUDY OF SACITUZUMAB GOVITECAN-HZIYIN IN PATIENTS WITH PREVIOUSLY TREATED MESOTHELIOMAS$5,263,281
· FY2024 · Defense Health Agency
EXPLOITING EPIGENETIC VULNERABILITIES IN BREAST CANCERS WITH CHROMOSOMAL INSTABILITY$5,184,545
· FY2025 · Defense Health Agency
NEW; TITLE: INTEGRATED MANHATTAN PROJECT FOR EXCELLENCE IN RADIOCHEMISTRY (IMPER); PI: JASON LEWIS$4,800,000
· FY2009 · Department of Energy
INFLUENCE TRIAL: IMPROVING EVENT-FREE SURVIVAL BY OPTIMIZING FLUDARABINE EXPOSURE DURING LYMPHODEPLETION FOR CAR T CELL THERAPY$4,029,612
· FY2024 · Defense Health Agency
TARGETING MASTER REGULATORS OF THE BREAST CANCER METASTASIS TRANSCRIPTOME$3,961,270
· FY2013 · Department of Defense
COMPARATIVE EFFECTIVENESS OF ACUPUNCTURE FOR CHRONIC PAIN AND CO-MORBID CONDITIONS IN VETERANS$3,950,202
· FY2015 · Department of the Army
TUMOR ANTIGEN-TARGETED T-CELL THERAPY FOR METASTATIC BREAST CANCER$2,921,237
· FY2014 · Department of the Army
NEW AWARD - IMPACT OF GERMLINE GENETIC TESTING FOR MEN WITH PROSTATE CANCER ON ACTIVE SURVEILLANCE, EFFECTIVE 4/1/2020, SIGNED 3/13/2020, DISTRIBUTED 3/17/2020, FAADC 3/17/2020$2,744,029
· FY2020 · Defense Health Agency
TUMOR ANTIGEN-TARGETED T-CELL THERAPY FOR METASTATIC BREAST CANCER$2,711,356
· FY2014 · Department of the Army
PHASE 1 STUDY OF HUMANIZED 3F8 MONOCLONAL ANTIBODY (HU3F8) IN PATIENTS WITH HIGH-RISK NEUROBLASTOMA AND GD2-POSITIVE TUMORS$2,680,415
· FY2012 · Department of Defense
REGIONAL IMMUNE INTERVENTIONS TO ENHANCE MESOTHELIN-TARGETED IMMUNOTHERAPY OF MALIGNANT PLEURAL MESOTHELIOMA$2,658,119
· FY2011 · Department of the Army
NEW AWARD - DEFINING TRANSCRIPTION FACTOR NETWORKS GOVERNING ANDROGEN RECEPTOR-NULL PROSTATE CANCER...SIGNED 06-MAY-2020, EFFECTIVE 30 SEP 2020, DISTRIBUTED MAY 12, 2020, FAADC 5/12/2020$2,655,000
· FY2020 · Department of the Army